What Tarveda Therapeutics does

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — a proprietary class of targeted therapeutics that pairs a tumor-targeting ligand with a cytotoxic payload engineered to concentrate drug activity in solid tumor tissue while limiting systemic exposure. Founded in 2012 in Watertown, Massachusetts by Stephen J. Lippard (a recognized authority in platinum-based anticancer chemistry), the company is led by Chairman Drew Fromkin, Chief Scientific Officer Mark Bilodeau, and Chief Medical Officer Jeffrey Bloss, with corporate development supported by EVP of Strategy Sudha Kadiyala. The platform is structurally applicable across multiple solid tumor indications, which supports a pipeline-program strategy rather than a single-asset focus.

The business model is purely R&D-driven and pre-revenue. Tarveda has no marketed product, no disclosed licensing revenue, no pricing model, and no commercial customer base. Value creation depends entirely on advancing clinical milestones, de-risking the pipeline, and ultimately enabling either a strategic exit (acquisition or partnership with a large pharmaceutical company) or further equity financing. To date the company has raised approximately $148 million across nine disclosed rounds between 2012 and 2021, with backing from tier-1 biotech investors Flagship Pioneering, New Enterprise Associates (NEA), Novo Holdings, Versant Ventures, and ND Capital. The largest single rounds were a $38 million Series D in January 2016 (led by Novo Holdings) and a $30 million Series E in February 2017 (led by Versant Ventures); subsequent raises have been materially smaller, and the most recent disclosed round is a ~$6 million insider-heavy SEC Form D offering filed in September 2021 under Rule 506(b).

The company's operating footprint is a single headquarters in Watertown, Massachusetts, with a headcount of 11–50 employees. The corporate website (tarvedatx.com) currently displays Indonesian-language online-gambling content rather than corporate material, which strongly indicates the domain is no longer actively maintained and is a soft negative signal about current operational health. Geographic markets served are limited to the United States. There is no disclosed regulatory approval, no FDA-cleared product, and no public listing.

Name

Tarveda Therapeutics

Legal name

Tarveda Therapeutics, Inc.

Website

https://tarvedatx.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Tarveda Therapeutics is a clinical-stage biopharmaceutical company developing miniature drug conjugates — targeted therapies combining a ligand with a cytotoxic payload — for solid tumors. Founded in 2012 in Watertown, Massachusetts, the company is venture-backed and pre-revenue.

Ownership category

akta.pro rank

Product category

Targeted Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Miniature drug conjugates
• Solid tumor therapeutics
• Oncology drug development
• Targeted cancer therapy
• Conjugate drug platform

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Tarveda Therapeutics is a developer of miniature drug conjugates — a class of targeted therapeutics — designed for the treatment of patients with a wide range of solid tumors. The company's pipeline leverages a proprietary conjugate platform aimed at delivering potent cytotoxic agents selectively to solid tumor tissue. Activities span discovery, preclinical, and clinical development of these oncology candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• Miniature Drug Conjugate Platform Proprietary platform of miniature drug conjugates — targeted therapeutics combining a targeting ligand, linker, and cytotoxic warhead — engineered for the treatment of patients with a wide range of solid tumors.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• ImmunoGen: Pioneer in antibody-drug conjugates for solid tumors, now part of AbbVie. Directly comparable to Tarveda as a developer of targeted cytotoxic conjugates for oncology indications.
• Mersana Therapeutics: Clinical-stage ADC developer focused on solid tumors with proprietary linker and payload platforms. Directly comparable as a small-cap, clinical-stage oncology conjugate developer.
• CytomX Therapeutics: Developer of Probody therapeutics, conditionally activated antibody-based agents for solid tumors. Comparable as a clinical-stage oncology platform using engineered protein constructs to improve tumor selectivity.
• ADC Therapeutics: Late-stage ADC developer with approved and clinical-stage oncology assets. Comparable as a focused ADC company developing targeted cytotoxic conjugates for solid and hematologic tumors.
• Bolt Biotherapeutics: Developer of immune-stimulating antibody conjugates for solid tumors. Comparable as a small-cap oncology platform company using conjugate chemistry to drive tumor-targeted therapeutics.
• Heidelberg Pharma: ADC developer using proprietary amanitin payload technology for solid tumors. Comparable as a clinical-stage company building novel cytotoxic conjugate platforms for oncology.
• Pyxis Oncology: Clinical-stage developer of ADC and immuno-oncology candidates for solid tumors. Comparable as a venture-backed oncology platform company developing targeted therapeutics.

Emerging players

• Mythic Therapeutics: Emerging ADC developer focused on solid tumors using protein-engineering approaches. Comparable as an early-stage player pursuing next-generation conjugate formats, similar to Tarveda's miniaturized approach.
• Tubulis: European preclinical-stage ADC developer with proprietary linker chemistry. Comparable as an emerging player in next-generation targeted oncology conjugates.

Broad incumbents

• Pfizer: Large pharma with significant ADC and solid-tumor oncology franchises (e.g., through Seagen acquisition). Relevant as a potential acquirer or BD partner for clinical-stage oncology conjugate developers like Tarveda.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/blend-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tarveda Therapeutics